Billiontoone (NASDAQ:BLLN) CTO David Tsao Sells 20,000 Shares of Stock

Billiontoone, Inc. (NASDAQ:BLLN) CTO David Tsao sold 20,000 shares of the firm’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $109.24, for a total transaction of $2,184,800.00. Following the sale, the chief technology officer owned 1,000 shares of the company’s stock, valued at approximately $109,240. The trade was a 95.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Tsao also recently made the following trade(s):

• On Monday, October 5th, David Tsao sold 20,000 shares of Billiontoone stock. The stock was sold at an average price of $108.15, for a total transaction of $2,163,000.00.
• On Thursday, September 24th, David Tsao sold 3,333 shares of Billiontoone stock. The shares were sold at an average price of $125.00, for a total transaction of $416,625.00.
• On Wednesday, September 9th, David Tsao sold 20,000 shares of Billiontoone stock. The shares were sold at an average price of $98.77, for a total transaction of $1,975,400.00.
• On Tuesday, August 25th, David Tsao sold 10,000 shares of Billiontoone stock. The shares were sold at an average price of $100.00, for a total transaction of $1,000,000.00.
• On Monday, August 10th, David Tsao sold 10,000 shares of Billiontoone stock. The stock was sold at an average price of $92.86, for a total transaction of $928,600.00.

Billiontoone Stock Up 3.1%

BLLN stock opened at $113.89 on Thursday. The firm has a market cap of $5.37 billion and a PE ratio of 162.70. The company has a debt-to-equity ratio of 0.17, a quick ratio of 11.31 and a current ratio of 11.69. The firm’s 50 day moving average price is $104.67 and its 200-day moving average price is $96.89. Billiontoone, Inc. has a one year low of $61.96 and a one year high of $150.44.

Billiontoone (NASDAQ:BLLN) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.15 EPS for the quarter, meeting analysts’ consensus estimates of $0.15. The firm had revenue of $109.45 million for the quarter. Billiontoone had a return on equity of 9.96% and a net margin of 8.04%. On average, equities research analysts anticipate that Billiontoone, Inc. will post 0.80 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. JPMorgan Chase & Co. decreased their price target on Billiontoone from $145.00 to $130.00 and set an “overweight” rating on the stock in a research note on Thursday, August 6th. Zacks Research upgraded Billiontoone from a “strong sell” rating to a “hold” rating in a report on Friday, October 2nd. Wall Street Zen downgraded Billiontoone from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Canaccord Genuity Group assumed coverage on shares of Billiontoone in a report on Wednesday, September 2nd. They issued a “buy” rating and a $120.00 price objective on the stock. Finally, Guggenheim upped their target price on shares of Billiontoone from $125.00 to $128.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Billiontoone has a consensus rating of “Moderate Buy” and a consensus price target of $126.25.

Institutional Investors Weigh In On Billiontoone

A number of institutional investors have recently modified their holdings of the company. Wasatch Advisors LP grew its position in Billiontoone by 40.2% in the 2nd quarter. Wasatch Advisors LP now owns 518,084 shares of the company’s stock valued at $62,160,000 after acquiring an additional 148,446 shares in the last quarter. Emerald Advisers LLC increased its stake in Billiontoone by 26.8% during the first quarter. Emerald Advisers LLC now owns 239,562 shares of the company’s stock worth $18,911,000 after purchasing an additional 50,613 shares during the period. Penn Capital Management Company LLC increased its stake in Billiontoone by 2.3% during the third quarter. Penn Capital Management Company LLC now owns 132,636 shares of the company’s stock worth $14,143,000 after purchasing an additional 3,034 shares during the period. Emerald Mutual Fund Advisers Trust increased its stake in Billiontoone by 11.9% during the first quarter. Emerald Mutual Fund Advisers Trust now owns 132,206 shares of the company’s stock worth $10,436,000 after purchasing an additional 14,072 shares during the period. Finally, Perceptive Advisors LLC lifted its position in shares of Billiontoone by 26.1% during the first quarter. Perceptive Advisors LLC now owns 91,812 shares of the company’s stock worth $7,248,000 after purchasing an additional 19,000 shares in the last quarter.

More Billiontoone News

Here are the key news stories impacting Billiontoone this week:

• Positive Sentiment: Q3 results topped expectations: Revenue was about $123.0 million, above the $115.8 million FactSet estimate. Reported earnings per share also exceeded the $0.16 consensus, although sources cite different actual EPS figures ($0.32 and $0.48). BillionToOne Q3 results and guidance
• Positive Sentiment: Higher 2026 revenue guidance: The company raised its full-year revenue outlook, signaling improved expectations for growth. Company announcement
• Negative Sentiment: Multiple insiders sold shares: The CEO, CTO and an SVP reported sales. The transactions were made under pre-arranged Rule 10b5-1 plans, which may temper—but do not eliminate—the bearish signal investors could take from insider selling. Insider transaction reports

About Billiontoone

BillionToOne, Inc is a molecular diagnostics company that develops tests designed to provide more sensitive and quantitative genetic information from blood samples. The company’s technology is based on its proprietary Quantitative Counting Template (QCT) platform, which is designed to measure DNA molecules with high sensitivity and support the detection of clinically meaningful genetic signals.

The company’s products include prenatal diagnostic and screening solutions marketed under the UNITY brand.